NCT07403630Recruiting
INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)
Source: ClinicalTrials.gov · Last updated 17 Feb 2026
Brief summary (registry, in English)
This is a multicenter, experimental preclinical study conducted on primary samples from patients diagnosed with hematological or solid neoplasms defined as high risk. The study will be prospective, based on the consecutive enrollment of eligible patients at each participating institution.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- First submitted
- 4 Feb 2026
- Start date
- 31 May 2023
- Primary completion date
- 28 Feb 2027
- Lead sponsor
- Azienda Ospedaliero-Universitaria di Parma
- Diseases
- Acute lymphoblastic leukaemia, Myeloproliferative neoplasms, Mesothelioma, Bladder cancer, Melanoma, Chronic lymphocytic leukaemia, Lung cancer, Pancreatic cancer, Multiple myeloma, Ovarian cancer, Childhood cancers
- NCT number
- NCT07403630
What you commit to
- Study type: Interventional
- Planned participants: 300
- From 31 May 2023 to the primary completion date, 28 Feb 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with active, uncontrolled infections
Age
- Patients younger than 1 year old
Who the study is looking for
- Patients aged one year and over who are referred to the centres involved in the protocol (Azienda Ospedaliero-Universitaria di Parma, University of Parma, University of Perugia and Azienda Ospedali Riuniti Villa Sofia-Cervello of Palermo).
- Patients with an established diagnosis of haematological or solid organ malignancy, including haematological or solid malignancies characteristic of the paediatric age group.
- Patients diagnosed with relapsed, refractory and/or metastatic haematological or solid malignancy. Patients may be enrolled regardless of the extent and type of previous therapy. Patients may also be enrolled if they are undergoing active treatment at the time of evaluation.
- Patients must have the capacity to understand the investigative nature of the study and provide informed consent in writing. For patients under the age of 12 years, consent will be provided by the parent/legal guardian according to international guidelines. For patients aged 12 to 17 years, consent will be provided by the patient and the parent/legal guardian according to the mature minor principle.
Age in the registry: 1 year to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| AO Riuniti Villa Sofia-Cervello di Palermo Coordinator of this site? Confirm its status | Palermo | Italy | Recruiting |
| University of Perugia Coordinator of this site? Confirm its status | Perugia | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.